-
EP2585470
European procedure
Extract from the Register of European Patents
EP About this file: EP2585470
| EP2585470 - NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY [Right-click to bookmark this link] | |||
| Former [2013/18] | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY | ||
| [2016/32] | Status | No opposition filed within time limit Status updated on 01.12.2017 Database last updated on 12.11.2024 | |
| Former | The patent has been granted Status updated on 23.12.2016 | ||
| Former | Grant of patent is intended Status updated on 16.12.2016 | ||
| Former | Examination is in progress Status updated on 18.11.2016 | Most recent event Tooltip | 01.12.2017 | Lapse of the patent in a contracting state | published on 03.01.2018 [2018/01] | 01.12.2017 | No opposition filed within time limit | published on 03.01.2018 [2018/01] | Applicant(s) | For all designated states Hanmi Science Co., Ltd. 550 Dongtangiheung-ro Dongtan-myeon Hwaseong-si Gyeonggi-do 445-813 / KR | [2017/04] |
| Former [2013/18] | For all designated states Hanmi Science Co., Ltd. 550 Dongtangiheung-ro Dongtan-myeon Hwaseong-si Gyeonggi-do 445-813 / KR | Inventor(s) | 01 /
CHA, Mi Young Hanlla Apt. 306-1102 Cheongsolmaeul Geumgok-dong Bundang-gu Seongnam-si Gyeonggi-do 463-725 / KR | 02 /
KANG, Seok Jong 174-1 Jamo-ri Gunbuk-myeon Okcheon-gun Chungcheongbuk-do 373-853 / KR | 03 /
KIM, Mi Ra 102-ho 7-31 Yangjae-dong Seocho-gu Seoul 137-130 / KR | 04 /
LEE, Ju Yeon Hoban 2-cha Apt. 215-202 Wolgae-dong Gwangsan-gu Gwangju 506-773 / KR | 05 /
JEON, Ji Young Mokryeon Apt. 1213-202 Sanbon-dong Gunpo-si Gyeonggi-do 435-040 / KR | 06 /
JO, Myoung Gi Seongwon 2-cha 202-1106 Anyang-4-dong Manan-gu Anyang-si Gyeonggi-do 430-014 / KR | 07 /
KWAK, Eun Joo 303-4 Seogwi-dong Seogwipo-si Jeju-do 679-010 / KR | 08 /
LEE, Kwang Ok LG Xi Apt. 912-401 Sanghyeon-2-dong Suji-gu Yongin-si Gyeonggi-do 448-132 / KR | 09 /
HA, Tae Hee Seohae Grable 413-2101 Solbitmaeul Bansong-dong Hwaseong-si Gyeonggi-do 445-758 / KR | 10 /
SUH, Kwee Hyun Greenville Apt. 101-204 1258 Maetan-3-dong Youngtong-gu Suwon-si Gyeonggi-do 443-848 / KR | 11 /
KIM, Maeng Sup Dunchon Jugong Apt. 301-203 Dunchon-dong Gangdong-gu Seoul 134-060 / KR | [2013/18] | Representative(s) | Suarez-Miles, Ana Sanchiz, et al Eli Lilly and Company Limited Lilly Research Centre Erl Wood Manor Sunninghill Road Windlesham, Surrey GU20 6PH / GB | [2017/04] |
| Former [2013/18] | Towler, Philip Dean Dehns St Bride's House 10 Salisbury Square London EC4Y 8JD / GB | Application number, filing date | 11798350.2 | 20.06.2011 | [2017/04] | WO2011KR04482 | Priority number, date | KR20100059686 | 23.06.2010 Original published format: KR 20100059686 | [2013/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2011162515 | Date: | 29.12.2011 | Language: | EN | [2011/52] | Type: | A2 Application without search report | No.: | EP2585470 | Date: | 01.05.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.12.2011 takes the place of the publication of the European patent application. | [2013/18] | Type: | B1 Patent specification | No.: | EP2585470 | Date: | 25.01.2017 | Language: | EN | [2017/04] | Search report(s) | International search report - published on: | KR | 03.05.2012 | (Supplementary) European search report - dispatched on: | EP | 04.12.2013 | Classification | IPC: | C07D495/04, C07D409/12, A61K31/4365, A61P35/00 | [2013/18] | CPC: |
C07D495/04 (EP,KR,RU,US);
C07D491/048 (EP,CN,US);
A61K31/519 (EP,CN,KR,RU,US);
A61K31/5377 (EP,CN,US);
A61K31/538 (EP,US);
A61K31/541 (EP,US);
A61K31/55 (EP,US);
A61K31/553 (EP,US);
A61K31/675 (EP,US);
A61K45/06 (EP,US);
A61P1/00 (EP);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (EP);
A61P11/08 (EP);
A61P13/12 (EP);
A61P17/00 (EP);
A61P17/04 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P19/06 (EP);
A61P25/00 (EP);
A61P25/02 (EP);
A61P25/04 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P35/04 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/04 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P5/14 (EP);
A61P7/04 (EP);
A61P7/10 (EP);
A61P9/00 (EP);
A61P9/04 (EP);
A61P9/10 (EP);
C07D409/12 (KR);
C07D491/04 (EP,US);
C07D493/04 (EP,US);
C07D519/00 (EP,US);
| C-Set: |
C07D491/04, A61K45/06 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/18] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | NEUE FUSIONIERTE PYRIMIDINDERIVATE ZUR HEMMUNG EINER TYROSINKINASEAKTIVITÄT | [2013/18] | English: | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | [2016/32] | French: | NOUVEAUX DÉRIVÉS FUSIONNÉS DE PYRIMIDINE POUR L'INHIBITION DE L'ACTIVITÉ TYROSINE KINASE | [2013/18] |
| Former [2013/18] | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY | Entry into regional phase | 22.01.2013 | National basic fee paid | 22.01.2013 | Search fee paid | 22.01.2013 | Designation fee(s) paid | 22.01.2013 | Examination fee paid | Examination procedure | 22.01.2013 | Examination requested [2013/18] | 26.06.2014 | Amendment by applicant (claims and/or description) | 13.04.2015 | Despatch of a communication from the examining division (Time limit: M06) | 22.10.2015 | Reply to a communication from the examining division | 25.11.2015 | Despatch of a communication from the examining division (Time limit: M06) | 06.04.2016 | Reply to a communication from the examining division | 01.08.2016 | Communication of intention to grant the patent | 15.11.2016 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 15.11.2016 | Fee for grant paid | 15.11.2016 | Fee for publishing/printing paid | 15.12.2016 | Information about intention to grant a patent | 15.12.2016 | Receipt of the translation of the claim(s) | Divisional application(s) | EP15181011.6 / EP2975042 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 13.04.2015 | Opposition(s) | 26.10.2017 | No opposition filed within time limit [2018/01] | Fees paid | Renewal fee | 26.06.2013 | Renewal fee patent year 03 | 11.03.2014 | Renewal fee patent year 04 | 17.06.2015 | Renewal fee patent year 05 | 03.08.2016 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 30.06.2016 | 06 M06 Fee paid on 03.08.2016 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | SM | 25.01.2017 | [2018/01] | Documents cited: | Search | [Y]WO2009062258 (CYTOPIA RES PTY LTD [AU], et al) [Y] 1-14 * example 30; claims 1-16; compounds 3, 5 *; | [Y]WO2009158571 (AVILA THERAPEUTICS AND USES TH [US], et al) [Y] 1-14 * examples 251, 252, 264, 265, 270, 271, 279; claims 1-34, 36-41, 43-46, 48, 49, 51, 52, 54-66; tables 6, 14, 16, 17, 18; compounds I1-5, I7-9, I12-15, I17, I23, I28-39, I42-52, I54, *; | [A]WO2010054285 (NAT HEALTH RESEARCH INSTITUTES, et al) [A] 1-14* claims 1-37; compounds 4-8, 31-54, 118-128, 236-247, 282-301 * | International search | [A]WO9802438 (GLAXO GROUP LTD [GB], et al); | [A] - H. D. HOLLIS SHOWALTER ET AL., "Tyrosine kinase Inhibitor. 16. 6,5,6- tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5-b] indoles as inhibitors of the epidermal growth factor receptor tyrosine kinase", J. MED. CHEM., (1999), vol. 42, pages 5464 - 5474, XP002210181 DOI: http://dx.doi.org/10.1021/jm9903949 | [A] - SUSANNE TRUMPP-KALLMEYER ET AL., "Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors", J. MED. CHEM., (1998), vol. 41, pages 1752 - 1763, XP002164517 DOI: http://dx.doi.org/10.1021/jm970634p | [A] - PETER TRAXLER ET AL., "Use of a pharmacophore model for the design of EGR-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines", J. MED. CHEM., (1997), vol. 40, no. 22, pages 3601 - 3616, XP001009913 DOI: http://dx.doi.org/10.1021/jm970124v | by applicant | WO2008073785 | WO2008152394 | - WILLIAM G. KAELIN JR., NATURE REVIEWS CANCER, (2005), vol. 5, page 689 | - DOUGLAS HANAHAN; ROBERT A. WEINBERG, CELL, (2000), vol. 100, page 57 | - IRENA MELNIKOVA; JAMES GOLDEN, NATURE REVIEWS DRUG DISCOVERY, (2004), vol. 3, page 993 | - NANCY E. HYNES; HEIDI A. LANE, NATURE REVIEWS CANCER, (2005), vol. 5, page 341 | - WILLIAM PAO ET AL., PUBLIC LIBRARY OF SCIENCE MEDICINE, (2005), vol. 2, no. 3, page 225 | - CANCER RES, (2007), vol. 67, no. 24, page 11924 | - DANAN LI ET AL., CANCER CELL, (2007), vol. 12, page 81 | - ANJA MICHALCZYK ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, (2008), vol. 16, page 3482 | - C H MOM ET AL., BRITISH JOURNAL OF CANCER, (2007), vol. 98, page 80 | - ENGELMAN JA ET AL., CANCER RES., (2007), vol. 67, page 11924 | - TSUYOSHI SUZUKI ET AL., CANCER SCI., (2007), vol. 98, no. 12, page 1977 | - DAVID W. FRY ET AL., PROC. NATL. ACAD. SCI. USA., (1998), vol. 95, page 12022 | - JEFF B. SMAILL ET AL., J MED. CHEM., (1999), vol. 42, page 1803 | - MARTIN L. SOS ET AL., CANCER RES., (2010), vol. 70, page 868 | - KHAN ET AL., IMMUNITY, (1995), vol. 3, page 283 | - ELLMEIER ET AL., J EXP. MED., (2000), vol. 192, page 1611 | - KUROSAKI, CURRENT OPINION IN IMMUNOLOGY, (2000), vol. 12, page 276 | - SCHAEFFER; SCHWARTZBERG, CURRENT OPINION IN IMMUNOLOGY, (2000), vol. 12, page 282 | - JANSSON; HOLMDAHL, CLIN. EXP. 1MMUNOL, (1993), vol. 94, page 459 | - PAN ET AL., CHEM, MED CHEM., (2007), vol. 2, page 58 | - IWAKI ET AL., J. BIOL. CHEM., (2005), vol. 280, page 40261 | - HORWOOD ET AL., J EXP MED., (2003), vol. 197, page 1603 | - ISLAM; SMITH, IMMUNOL. REV., (2000), vol. 178, page 49 | - FELDHAHN ET AL., J EXP. MED., (2005), vol. 201, page 1837 | - FLANAGAN ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (2010), vol. 53, page 8468 | - PESU M; LAURENCE A; KISHORE N ET AL., IMMUNOL REV, (2008), vol. 223, page 132 | - KAWAHARA A; MINAMI Y; MIYAZAKI T ET AL., PROC NATL ACAD SCI USA, (1995), vol. 92, page 8724 | - NOSAKA T; VAN DEURSEN JMA; TRIPP RA ET AL., SCIENCE, (1995), vol. 270, page 800 | - PAPAGEORGIOU AC; WIKMAN LEK ET AL., TRENDS PHARM SCI, (2004), vol. 25, page 558 | - PAMELA L. SCHWARTZBERG ET AL., NATURE REVIEWS IMMUNOLOGY, (2005), vol. 5, no. 284 | - SCHAEFFER ET AL., SCIENCE, (1999), vol. 284, page 638 | - FOWELL ET AL., IMMUNITY, (1999), vol. 11, page 399 | - SCHAFFER ET AL., NATURE IMMUNOLOGY, (2001), vol. 2, page 1183 | - MULLER ET AL., JOURNAL OF IMMUNOLOGY, (2003), vol. 170, page 5056 | - MATSUMOTO ET AL., INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, (2002), vol. 129, page 327 | - SCHAEFFER ET AL., NATURE IMMUNOLOGY, (2001), vol. 2, page 1183 | - SCHAEFFER ET AL., SCIENCE, (1999), vol. 284, page 63 8 | - PAN ET AL., MOL, CELL. BIOL., (2002), vol. 22, page 7512 | - WOOYOUNG HUR ET AL., BIOORG. MED. CHEM. LETT., (2008), vol. 18, page 5916 | - DAVID D BRAND ET AL., NATURE PROTOCOL., (2007), vol. 2, no. 5, page 1269 |